1
939–1947; (c) A. E. Girard, D. Girard, A. R. English, T. D. Gootz,
Chem., Int. Ed., 2008, 47, 2808–2812; (d) E. E. Wyatt, S. Fergus, W. R.
J. D. Galloway, A. Bender, D. J. Fox, A. T. Plowright, A. S. Jessiman,
M. Welch and D. R. Spring, Chem. Commun., 2006, 3296–3298.
18 N. Hoffmann, B. Lee, M. Hentzer, T. B. Rasmussen, Z. J. Song, H. K.
Johansen, M. Givskov and N. Hoiby, Antimicrob. Agents Chemother.,
2007, 51, 3677–3687. Recent work by Hoffmann et al. has demonstrated
that the bacterial ribosome is important to the action of azithromycin
at sub-MIC values. The work reported herein supports this view.
19 The synthesis of azithromycin is patented by Pliva and Pfizer. Patents
US 3 478 014; US 4 328 334; US 4 474 768. For a review of this and
more recent synthetic efforts, see: Y.-J. Wu, Curr. Pharm. Des., 2000, 6,
181–223.
C. R. Cimochowski, J. A. Faiella, S. L. Haskell and J. A. Retsema,
Antimicrob. Agents Chemother., 1987, 31, 1948–1954.
M. Shinkai, M. O. Henke and B. K. Rubin, Pharmacol. Ther., 2008,
5
6
7
1
17, 393–405 and references therein.
R. A. Howe and R. C. Spencer, J. Antimicrob. Chemother., 1997, 40,
1
53–155.
The use of azithromycin to treat cystic fibrosis: (a) J. G. McCormack
and S. C. Bell, Intern. Med. J., 2005, 35, 73–74; (b) A. Jaffe, J. Francis, M.
Rosenthal and A. Bush, Lancet, 1998, 351, 420; (c) J. Wolter, S. Seeney,
S. Bell, S. Bowler, P. Masel and J. McCormack, Thorax, 2002, 57,
2
12–216; (d) A. Equi, I. M. Balfour-Lynn, A. Bush and M. Rosenthal,
Lancet, 2002, 360, 978–984; (e) L. Saiman, B. C. Marshall, N. Mayer-
Hamblett, J. L. Burns, A. L. Quittner, D. A. Cibene, S. Coquillette,
A. Y. Fieberg, F. J. Accurso and P. W. Campbel, JAMA, J. Am. Med.
Assoc., 2003, 290, 1749–1756.
20 D. Pandey, S. B. Katti, W. Haq and C. K. M. Tripathi, Bioorg. Med.
Chem., 2004, 12, 3807–3813.
21 (a) C. Djokic and Z. Tamburasev, Tetrahedron Lett., 1967, 8, 1647;
(b) R. S. Egan, L. A. Freiberg and W. H. Washburn, J. Org. Chem.,
1974, 39, 2492–2494.
8
9
F. Ratjen and G. Doring, Lancet, 2003, 361, 681–689.
(a) J. C. Davies, Paediatr. Respir. Rev., 2002, 3, 128–134; (b) J. B. Lyczak,
C. L. Cannon and G. B. Pier, Clin. Microbiol. Rev., 2002, 15, 194–222;
22 S. Djokic, G. Kobrehel, G. Lazarevski, N. Lopotar, Z. Tamburasev, B.
Kamenar, A. Nagl and I. Vickovic, J. Chem. Soc., Perkin Trans. 1, 1986,
1881–1890.
(
c) S. Rajan and L. Saiman, Semin. Respir. Infect., 2002, 17, 47–56.
1
1
1
0 F. Schlunzen, J. M. Harms, F. Franceschi, H. A. S. Hansen, H. Bartels,
3
23 In CDCl the product isomerized. This has been observed previously:
R. Zarivach and A. Yonath, Structure (Cambridge, MA, U. S.), 2003,
B. W. V. Yang, M. Goldsmith and J. P. Rizzi, Tetrahedron Lett., 1994,
1
1, 329–338.
35, 3025–3028.
1 For recent studies see: T. Kohler, J. L. Dumas and C. Van Delden,
Antimicrob. Agents Chemother., 2007, 51, 4243–4248. For previous
studies see references therein.
2 For recent studies see: (a) K. Tateda, R. Comte, J. C. Pechere, T. Kohler,
K. Yamaguchi and C. Van Delden, Antimicrob. Agents Chemother.,
24 R. R. Wilkening, R. W. Ratcliffe, G. A. Doss, R. T. Mosley and R. G.
Ball, Tetrahedron, 1997, 53, 16923–16944.
25 R. R. Wilkening, R. W. Ratcliffe, G. A. Doss, K. F. Bartizal, A. C.
Graham and C. M. Herbert, Bioorg. Med. Chem. Lett., 1993, 3, 1287–
1292.
2
001, 45, 1930–1933; (b) Y. Nalca, L. Jansch, F. Bredenbruch, R.
Geffers, J. Buer and S. Hussler, Antimicrob. Agents Chemother., 2006,
0, 1680–1688.
26 H Mikkelsen, Z. Duck, K. S. Lilley and M. Welch, J. Bacteriol., 2007,
189, 2411–2416.
5
27 (a) L. Burdine and T. Kodadek, Chem. Biol., 2004, 11, 593–597; (b) B.
J. Leslie and P. J. Hergenrother, Chem. Soc. Rev., 2008, 37, 1347–
1360.
1
1
1
3 For investigations into the effect of azithromycin on biofilm formation
see: (a) S. Favre-Bonte, T. Kohler and C. Van Delden, J. Antimicrob.
Chemother., 2003, 52, 598–604; (b) R. J. Gillis and B. H. Iglewski, J.
Clin. Microbiol., 2004, 42, 5842–5845.
4 (a) L. Hall-Stoodley, J. W. Costerton and P. Stoodley, Nat. Rev.
Microbiol., 2004, 2, 95–108; (b) D. Davies, Nat. Rev. Drug Discovery,
28 This approach has previously been reported under similar reducing
conditions: (a) G. M. Bright, A. A. Nagel, J. Bordner, K. A. Desai, J. N.
Dibrino, J. Nowakowska, L. Vincent, R. M. Watrous, F. C. Sciavolino,
A. R. English, J. A. Retsema, M. R. Anderson, L. A. Brennan, R. J.
Borovoy, C. R. Cimochowski, J. A. Faiella, A. E. Girard, D. Girard,
C. Herbert, M. Manousos and R. Mason, J. Antibiot., 1988, 41, 1029–
1047; (b) M. B. Krajacic, N. Kujundzic, M. Dumic, M. Cindric, K.
Brajsa, B. Metelko and P. Novak, J. Antibiot., 2005, 58, 380–389.
29 For a description of the use of biotin-tagged analogues in target
identification projects see: R. J. Spandl, R. L. Nicholson, D. M.
Marsden, M. Welch and D. R. Spring, Synlett, 2008, 2122–2126. DOI:
10.1055/s-2008-1077978.
2
003, 2, 114–122; (c) D. J. Musk and P. J. Hergenrother, Curr. Med.
Chem., 2006, 13, 2163–2177.
5 (a) M. Welch, H. Mikkelsen, J. E. Swatton, D. Smith, G. L. Thomas, F.
G. Glansdorp and D. R. Spring, Mol. BioSyst., 2005, 1, 196–202; (b) J.
T. Hodgkinson, M. Welch and D. R. Spring, ACS Chem. Biol., 2007, 2,
7
15–717; (c) D. Smith, J.-H. Wang, J. E. Swatton, P. Davenport, B. Price,
H. Mikkelsen, H. Stickland, K. Nishikawa, N. Gardiol, D. R. Spring
and M. Welch, Sci. Prog. (St. Albans, U. K.), 2006, 89, 167–211; (d) F.
G. Glansdorp, G. L. Thomas, J. K. Lee, J. M. Dutton, G. P. C. Salmond,
M. Welch and D. R. Spring, Org. Biomol. Chem., 2004, 2, 3329–3336;
30 The acid 14 was synthesized in two steps from methyl bromoacetate
in excellent yield: J. A. Burlison and B. S. J. Blagg, Org. Lett., 2006, 8,
4855–4858.
(
e) L. Y. W. Lee, T. Hupfield, R. L. Nicholson, J. T. Hodgkinson, X.
Su, G. L. Thomas, G. P. C. Salmond, M. Welch and D. R. Spring, Mol.
BioSyst., 2008, 4, 505–507.
31 H. C. Kolb, M. G. Finn and K. B. Sharpless, Angew. Chem., Int. Ed.,
2001, 40, 2004.
1
1
6 P. K. Singh, A. L. Schaefer, M. R. Parsek, T. O. Moninger, M. J. Welsh
and E. P. Greenberg, Nature, 2000, 407, 762–764.
7 For instance, see: (a) E. E. Wyatt, W. R. J. D. Galloway, G. L. Thomas,
M. Welch, O. Loiseleur, A. T. Plowright and D. R. Spring, Chem.
Commun., 2008, DOI: 10.1039/b812901k; (b) A. Robinson, G. L.
Thomas, R. J. Spandl, M. Welch and D. R. Spring, Org. Biomol. Chem.,
32 V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, Angew.
Chem., Int. Ed., 2002, 41, 2596.
33 The reaction conditions were modified to account for the longer
reaction times required on the solid phase: S. V. Ley, I. R. Baxendale,
R. N. Bream, P. S. Jackson, A. G. Leach, D. A. Longbottom, M. Nesi,
J. S. Scott, R. I. Storer and S. J. Taylor, J. Chem. Soc., Perkin Trans. 1,
2000, 3815–4195.
2
008, 6, 2978–2981; (c) G. L. Thomas, R. J. Spandl, F. G. Glansdorp,
M. Welch, A. Bender, J. Cockfield, J. A. Lindsay, C. Bryant, D. F. J.
34 M. Bailey, T. Chettiath and A. S. Mankin, Antimicrob. Agents
Brown, O. Loiseleur, H. Rudyk, M. Ladlow and D. R. Spring, Angew.
Chemother., 2008, 52, 866–874.
4
124 | Org. Biomol. Chem., 2008, 6, 4120–4124
This journal is © The Royal Society of Chemistry 2008